Loading
Macrophage Migration Inhibitory Factor / Nuclear Receptors and Signaling · Journal article
Neuro-oncology Advances · September 10, 2026
Raises a question worth testing. It does not answer one.
This is an exploratory preclinical study proposing macrophage migration inhibitory factor (MIF) as a mediator of cisplatin-induced peripheral neuropathy in mouse models. MIF inhibition reduced mechanical hypersensitivity in treated mice, and circulating MIF was elevated in CisIPN animals, but the work remains mechanistic and has not been tested in patients or compared head-to-head to existing or candidate treatments.
Preclinical mechanistic study in mouse models. Normal and breast cancer mouse models with experimentally induced cisplatin-induced peripheral neuropathy. Intervention: Pharmacological inhibition of MIF using small molecule inhibitors. Compared with: Untreated CisIPN mice (control).
Circulating MIF levels were increased in CisIPN mice Pharmacological inhibition of MIF suppressed mechanical hypersensitivity component of CisIPN No significant change in macrophage abundance in DRGs and sciatic nerves of CisIPN mice
Pharmacological inhibition of MIF suppressed mechanical hypersensitivity component of CisIPN
This work identifies MIF as a mechanistic target in animal models of CisIPN and may inform future drug discovery; however, it does not yet provide evidence for clinical use or superiority over existing supportive care approaches. Translation to human disease and clinical efficacy trials would be necessary before any practice change.
Mechanistic preclinical study in mouse models proposing MIF as a therapeutic target; lacks clinical validation, hard endpoints, or translation to patient benefit.
As stated by the source record.
This work identifies MIF as a mechanistic target in animal models of CisIPN and may inform future drug discovery; however, it does not yet provide evidence for clinical use or superiority over existing supportive care approaches. Translation to human disease and clinical efficacy trials would be necessary before any practice change.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Background Cisplatin (CP) is a potent chemotherapy drug used for the management of several cancers. However, the use of CP is associated with painful peripheral neuropathy. Effective therapies are currently unavailable for cisplatin-induced peripheral neuropathy (CisIPN). Given the known association between pro-inflammatory cytokines and CisIPN, we explored the role of the pro-inflammatory cytokine, the macrophage migration inhibitory factor (MIF), in CisIPN. Methods CisIPN was induced in normal and breast cancer mouse models. Circulating MIF levels in CisIPN mice were examined using ELISA. The effect of MIF inhibition on CisIPN severity was evaluated using small molecule inhibitors. Mechanical and cold sensitivities of CisIPN mice were examined using von Frey filament and cold acetone assays. Macrophage infiltration and expression of MIF in dorsal root ganglia (DRG) and sciatic nerves of CisIPN mice were examined using immunostaining. Molecular changes downstream of MIF were examined in Schwann Cells (SCs) using western blot. Results Circulating MIF levels were increased in CisIPN mice, indicating a potential role for MIF in CisIPN. Pharmacological inhibition of MIF suppressed the mechanical hypersensitivity component associated with CisIPN, substantiating a facilitatory role for MIF in CisIPN. There was no significant change observed in macrophage abundance in DRGs and sciatic nerves of CisIPN mice. ELISA, immunostaining, and western blot assays indicated that sensory neurons and SCs are potential sources for increased MIF in CisIPN. We also found fluctuations in ERK1/2 signaling downstream of MIF in SCs, suggesting it as a potential mechanism underlying MIF-dependent facilitation of CisIPN. Conclusion Overall, our results indicate that MIF facilitates CisIPN, suggesting its potential role as a therapeutic target for CisIPN.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.